MarketPeel
Insider Trading Intelligence
YC

Yu-waye Chu

CTMX
CHIEF MEDICAL OFFICER · CYTOMX THERAPEUTICS, INC. · CIK 0001854586
FILING MIX · LIFETIME47%/53%
BUYS
17
SELLS
19
TOTAL VALUE
$1.31M
COMPANIES
2
ACTIVE SINCE
Apr 2021
HOLDINGS NOW
332,439
AVG SELL PX
$21.88
TRADE KIND
SHOWING 36 / 36
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
18 backtested trades · 8 horizons · 4 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Yu-waye Chu, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d18+33.33%+4.93%-1.56%+6.49%+5.26%
14d18+44.44%+8.69%-1.17%+9.86%+7.65%
30d18+50.00%-7.01%-1.25%-5.76%-2.23%
60d18+77.78%-2.48%-1.77%-0.72%-15.68%
90d18+94.44%-3.70%-1.96%-1.74%-18.53%
180d18(1 pending)+94.12%-28.04%-4.58%-23.46%-38.59%
1y18(1 pending)+94.12%-15.80%-2.02%-13.79%-46.37%
2y18(2 pending)+100.00%-90.29%+9.78%-100.07%-96.56%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CTMX · 189,446 shares · as of Mar 17, 2026
093,750187,500281,250375,000202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 17 buys / 19 sellsCOVERAGE · 20 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CTMX
CYTOMX THERAPEUTICS, INC.
SALE
Chief Medical Officer
21,279$6.42$136.7K189,446Mar 17, 2026Mar 19, 2026View →
CTMX
CYTOMX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
75,000210,725Feb 2, 2026Feb 4, 2026View →
CTMX
CYTOMX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
300,000300,000Feb 2, 2026Feb 4, 2026View →
CTMX
CYTOMX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
87,50087,500Sep 26, 2025Sep 30, 2025View →
CTMX
CYTOMX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
43,75043,750Sep 26, 2025Sep 30, 2025View →
CTMX
CYTOMX THERAPEUTICS, INC.
SALE
Chief Medical Officer
4,025$0.60$2.4K135,725Mar 18, 2025Mar 20, 2025View →
CTMX
CYTOMX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
115,000115,000Feb 4, 2025Feb 6, 2025View →
CTMX
CYTOMX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
57,500139,750Feb 4, 2025Feb 6, 2025View →
CTMX
CYTOMX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
56,00082,250Feb 4, 2025Feb 6, 2025View →
CTMX
CYTOMX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
238,000238,000Feb 4, 2025Feb 6, 2025View →
CTMX
CYTOMX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
75,00075,000Jan 18, 2024Jan 22, 2024View →
CTMX
CYTOMX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
26,25026,250Jan 18, 2024Jan 22, 2024View →
CTMX
CYTOMX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
122,500122,500Jan 18, 2024Jan 22, 2024View →
CTMX
CYTOMX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
375,000375,000Jul 19, 2023Jul 20, 2023View →
FATE
FATE THERAPEUTICS INC
SALE10b5-1
10b5-1 plan
2,317$6.58$15.2K140,676Apr 18, 2023Apr 19, 2023View →
FATE
FATE THERAPEUTICS INC
SALE10b5-1
10b5-1 plan
215$6.52$1.4K142,993Apr 18, 2023Apr 19, 2023View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
425,000425,000Feb 6, 2023Feb 7, 2023View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Medical Officer
7,825$5.24$41.0K143,208Jan 10, 2023Jan 11, 2023View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Medical Officer
4,062$35.37$143.7K151,033Apr 19, 2022Apr 21, 2022View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
53,05853,058Jan 25, 2022Jan 27, 2022View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
33,302155,095Jan 25, 2022Jan 27, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Senior VP Clinical Development
418$49.10$20.5K121,793Jan 11, 2022Jan 13, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Senior VP Clinical Development
3,547$48.44$171.8K122,211Jan 11, 2022Jan 13, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Senior VP Clinical Development
5$55.54$278125,758Dec 10, 2021Dec 13, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Senior VP Clinical Development
1,045$51.08$53.4K129,216Dec 10, 2021Dec 13, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Senior VP Clinical Development
2,097$49.32$103.4K131,161Dec 10, 2021Dec 13, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Senior VP Clinical Development
600$54.58$32.7K126,763Dec 10, 2021Dec 13, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Senior VP Clinical Development
900$50.42$45.4K130,261Dec 10, 2021Dec 13, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Senior VP Clinical Development
1,031$53.66$55.3K126,363Dec 10, 2021Dec 13, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Senior VP Clinical Development
1,822$52.37$95.4K127,394Dec 10, 2021Dec 13, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Senior VP Clinical Development
7,500105,000Dec 10, 2021Dec 13, 2021View →
FATE
FATE THERAPEUTICS INC
PURCHASE
Senior VP Clinical Development
7,500$16.32$122.4K133,258Dec 10, 2021Dec 13, 2021View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
60,958125,758Nov 19, 2021Nov 22, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Senior VP Clinical Development
875$81.80$71.6K67,200Apr 16, 2021Apr 20, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Senior VP Clinical Development
1,500$84.41$126.6K64,800Apr 16, 2021Apr 20, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Senior VP Clinical Development
900$82.91$74.6K66,300Apr 16, 2021Apr 20, 2021View →
Other insiders · CTMX
Loading peer insiders…
About this filer
CIK 0001854586
ROLE
Chief Medical Officer
PRIMARY
CTMX
COMPANIES
2
ACTIVE SINCE
Apr 2021
MARKETPEEL · /INSIDER/0001854586DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback